Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients

Breast Cancer Research and Treatment

Volumn 131, Issue 1, 2012, Pages 137-145

  Kiyotani, Kazuma ^a   Mushiroda, Taisei ^a   Imamura, Chiyo K ^b   Tanigawara, Yusuke ^b   Hosono, Naoya ^a   Kubo, Michiaki ^a   Sasa, Mitsunori ^c   Nakamura, Yusuke ^a,d   Zembutsu, Hitoshi ^d  

^a RIKEN   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c Tokushima Breast Care Clinic   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

CYP2D6; Endoxifen; P450 2D6; Single nucleotide polymorphisms; SNPs

Indexed keywords

AFIMOXIFENE; CYTOCHROME P450 2D6; ENDOXIFEN; TAMOXIFEN;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; ENDOMETRIAL DISEASE; EYE DISEASE; FATTY LIVER; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOT FLUSH; HUMAN; HYPERHIDROSIS; JAPANESE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALAISE; MENSTRUAL IRREGULARITY; NAUSEA; PHARMACOGENETICS; PRIORITY JOURNAL; STEADY STATE; TANDEM MASS SPECTROMETRY; THROMBOEMBOLISM; VAGINA DISCHARGE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; JAPAN; MIDDLE AGED; TAMOXIFEN;

EID: 84856164078     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1777-7     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 351 1451 1467 10.1016/S0140-6736(97)11423- 4 (Pubitemid 28227036)
2. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
3. JL Borgna H Rochefort 1981 Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues J Biol Chem 256 859 868 7451477 1:CAS:528:DyaL3MXps1Kluw%3D%3D (Pubitemid 11103040)
4. EA Lien E Solheim OA Lea S Lundgren S Kvinnsland PM Ueland 1989 Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment Cancer Res 49 2175 2183 2702659 1:STN:280:DyaL1M7psFWntQ%3D%3D (Pubitemid 19106533)
5. MD Johnson H Zuo KH Lee JP Trebley JM Rae RV Weatherman Z Desta DA Flockhart TC Skaar 2004 Pharmacological characterization of 4-hydroxy-N- desmethyl tamoxifen, a novel active metabolite of tamoxifen Breast Cancer Res Treat 85 151 159 15111773 10.1023/B:BREA.0000025406.31193.e8 1:CAS:528:DC%2BD2cXjsVertbc%3D (Pubitemid 38987269)
6. YC Lim L Li Z Desta Q Zhao JM Rae DA Flockhart TC Skaar 2006 Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells J Pharmacol Exp Ther 318 503 512 16690721 10.1124/jpet.105.100511 1:CAS:528:DC%2BD28XnslOls7o%3D (Pubitemid 44061223)
7. HS Lim JH Lee SK Lee SE Lee IJ Jang J Ro 2007 Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer J Clin Oncol 25 3837 3845 17761971 10.1200/JCO.2007.11.4850 1:CAS:528:DC%2BD2sXhtFanu7zK (Pubitemid 47477258)
8. Y Jin Z Desta V Stearns, et al. 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 30 39 15632378 10.1093/jnci/dji005 1:CAS:528:DC%2BD2MXisVaqsw%3D%3D
9. Z Desta BA Ward NV Soukhova DA Flockhart 2004 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 J Pharmacol Exp Ther 310 1062 1075 15159443 10.1124/jpet.104.065607 1:CAS:528:DC%2BD2cXnt1eqtb0%3D (Pubitemid 39108928)
10. HK Crewe LM Notley RM Wunsch MS Lennard EM Gillam 2002 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen Drug Metab Dispos 30 869 874 12124303 10.1124/dmd.30.8.869 1:CAS:528:DC%2BD38XlslWiu7w%3D (Pubitemid 34815415)
11. F Broly A Gaedigk M Heim M Eichelbaum K Morike UA Meyer 1991 Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population DNA Cell Biol 10 545 558 1681816 10.1089/dna.1991.10.545 1:CAS:528:DyaK3MXmslKmsb8%3D
12. C Sachse J Brockmoller M Hildebrand K Muller I Roots 1998 Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine Pharmacogenetics 8 181 185 10022755 10.1097/00008571-199804000-00010 1:CAS:528:DyaK1cXjs1OgsLo%3D (Pubitemid 28227325)
13. K Nakamura F Goto WA Ray CB McAllister E Jacqz GR Wilkinson RA Branch 1985 Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations Clin Pharmacol Ther 38 402 408 4042523 10.1038/clpt.1985.194 1:STN:280: DyaL28%2FgtlWksQ%3D%3D (Pubitemid 16250313)
14. H Yokota S Tamura H Furuya S Kimura M Watanabe I Kanazawa I Kondo FJ Gonzalez 1993 Evidence for a new variant CYP2D6 allele CYP2D6 J in a Japanese population associated with lower in vivo rates of sparteine metabolism Pharmacogenetics 3 256 263 8287064 10.1097/00008571-199310000-00005 1:CAS:528:DyaK2cXitFemtr0%3D (Pubitemid 23333095)
15. K Kiyotani T Mushiroda M Sasa Y Bando I Sumitomo N Hosono M Kubo Y Nakamura H Zembutsu 2008 Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy Cancer Sci 99 995 999 18294285 10.1111/j.1349-7006.2008.00780.x 1:CAS:528:DC%2BD1cXlslCrtrc%3D (Pubitemid 351997603)
16. MP Goetz JM Rae VJ Suman, et al. 2005 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 9312 9318 16361630 10.1200/JCO.2005.03.3266 1:CAS:528:DC%2BD28Xnt1ynuw%3D%3D
17. MP Goetz SK Knox VJ Suman, et al. 2007 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Breast Cancer Res Treat 101 113 121 17115111 10.1007/s10549-006-9428-0 1:CAS:528:DC%2BD2sXisVylsg%3D%3D (Pubitemid 47555336)
18. W Schroth L Antoniadou P Fritz M Schwab T Muerdter UM Zanger W Simon M Eichelbaum H Brauch 2007 Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes J Clin Oncol 25 5187 5193 18024866 10.1200/JCO.2007.12.2705 1:CAS:528:DC%2BD2sXhsVKnsbzN (Pubitemid 350232249)
19. Y Xu Y Sun L Yao, et al. 2008 Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment Ann Oncol 19 1423 1429 18407954 10.1093/annonc/mdn155 1:STN:280: DC%2BD1cvotVKmsA%3D%3D
20. W Schroth MP Goetz U Hamann, et al. 2009 Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen JAMA 302 1429 1436 19809024 10.1001/jama.2009.1420 1:CAS:528:DC%2BD1MXht1CksrjO
21. K Kiyotani T Mushiroda CK Imamura, et al. 2010 Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients J Clin Oncol 28 1287 1293 20124171 10.1200/JCO.2009.25.7246 1:CAS:528:DC%2BC3cXksFSqtb0%3D
22. J Gjerde J Geisler S Lundgren D Ekse JE Varhaug G Mellgren VM Steen EA Lien 2010 Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer BMC Cancer 10 313 20565970 10.1186/1471-2407-10-313
23. S Borges Z Desta L Li, et al. 2006 Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 61 74 16815318 10.1016/j.clpt.2006.03. 013 1:CAS:528:DC%2BD28Xms1enu7k%3D (Pubitemid 43946844)
24. JS Lim XA Chen O Singh YS Yap RC Ng NS Wong M Wong EJ Lee B Chowbay 2011 Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients Br J Clin Pharmacol 71 737 750 21480951 10.1111/j.1365-2125.2011.03905.x 1:CAS:528:DC%2BC3MXnsVSktL8%3D
25. N Hosono M Kato K Kiyotani, et al. 2009 CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection Clin Chem 55 1546 1554 19541866 10.1373/clinchem.2009.123620 1:CAS:528:DC%2BD1MXptleisL0%3D
26. Rae JM, Drury S, Hayes DF et al. (2010) Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endopoints in the ATAC trial. San Antonio Breast Cancer Symposium, San Antonio, Abstract S1-7
27. Leyland-Jones B, Regan MM, Bouzyk M et al. for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. (2010) Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. San Antonio Breast Cancer Symposium, San Antonio, Abstract S1-8
28. Irvin WJ, Jr., Walko CM, Weck KE et al. (2011) Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A Multicenter Study. J Clin Oncol 29(24):3232-3239
29. R Day 2001 Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National surgical adjuvant breast and bowel project Ann N Y Acad Sci 949 143 150 11795346 10.1111/j.1749-6632.2001.tb04012.x 1:CAS:528:DC%2BD38XnsFWruw%3D%3D (Pubitemid 34059970)
30. NL Henry JM Rae L Li, et al. 2009 Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort Breast Cancer Res Treat 117 571 575 19153830 10.1007/s10549-009-0309-1